The emergence of several new variants of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) in recent months has raised concerns around the potential impact on …

As of February 2022, 27 different COVID-19 vaccines have been authorised by one or more
regulatory authorities for specific or widespread use. 1 Of these, eight vaccines have …

Although infections among vaccinated individuals lead to milder COVID-19 symptoms
relative to those in unvaccinated subjects, the specificity and durability of antibody …

Background The use of an inactivated severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide …

Background Protection offered by coronavirus disease 2019 (COVID-19) vaccines wanes
over time, requiring an evaluation of different boosting strategies to revert such a trend and …

In late 2021, the omicron variant of SARS Coronavirus 2 (SARS-CoV-2) emerged and
replaced the previously dominant delta strain. Effectiveness of COVID-19 vaccines against …

There is a wealth of data suggesting that the effectiveness of existing vaccines against the
Omicron variant, the most mutated SARS-CoV-2 variant to date, has been substantially …

In light of the decreasing immune protection against symptomatic SARS-CoV-2 infection
after initial vaccinations and the now dominant immune-evasive Omicron variants,'booster' …

Virus neutralization data using post-vaccination sera are an important tool in informing
vaccine use policy decisions, however, they often pose interpretive challenges. We …

The new Omicron variant of SARS-CoV-2, first identified in November 2021, is rapidly
spreading all around the world. Omicron has become the dominant variant of SARS-CoV-2 …